New York, NY, November 30, 2006 - Daxor Corporation (AMEX:DXR): a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Sacred Heart Hospital of Allentown, Pennsylvania.
Sacred Heart Hospital is a 243-bed acute care facility with 20 skilled nursing beds located in the center of Allentown , the Lehigh Valley 's largest city. Sacred Heart Hospital provides a comprehensive range of advanced medical and surgical services. The Blood Volume Analyzer BVA-100 will be located in the Hospital’s Nuclear Medicine Department to diagnose blood volume derangements in hematology, cardiology and critical care.
Daxor’s Blood Volume Analyzer BVA-100 is the only FDA approved diagnostic device which is used by physician offices, diagnostic centers, small to large hospitals and university medical centers to determine a patient’s measured and ideal blood volume. By providing the latest technology in blood volume measurement, Sacred Heart Hospital continues its commitment to technological excellence and to be the preferred healthcare provider in the Greater Lehigh Valley.
Daxor Corporation manufactures and markets the BVA-100, a FDA approved, semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, a single use radiopharmaceutical diagnostic kit. For more information regarding Daxor Corporation’s Blood Volume Analyzer BVA-100, visit www.Daxor.com.